Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in <i>NPM1</i>-mutant AMLJan Philipp Bewersdorf, Maximilian Stahl, Rory M. Shallis et al.|Blood Advances|2024Cited by 12